Brief: Shanghai Junshi Biosciences Says Approval Of Supplemental NDA For Toripalimab
02/01/2024 15:16
Jan 2 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* APPROVAL OF SUPPLEMENTAL NDA FOR TORIPALIMAB AS
PERIOPERATIVE
TREATMENT FOR RESECTABLE NSCLC PATIENTS BY NMPA OF CHINA
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab